Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: A pilot study

Clinical Genitourinary Cancer

Volumn 5, Issue 1, 2006, Pages 50-56

  Majhail, Navneer S ^a   Wood, Laura ^b   Elson, Paul ^b   Finke, James ^d   Olencki, Thomas ^c   Bukowski, Ronald M ^b,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Immunotherapy; Metastases; Survival; Toxicity

Indexed keywords

INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPONATREMIA; KIDNEY CARCINOMA; LOW DRUG DOSE; MALE; MYALGIA; NAUSEA AND VOMITING; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PROTHROMBIN TIME; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; SIDE EFFECT; SKIN MANIFESTATION; ADJUVANT CHEMOTHERAPY; DOSE RESPONSE; DRUG ADMINISTRATION; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 33749063421     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.017     Document Type: Article

References (39)

1. Leibovich BC, Pantuck AJ, Bui MH, et al. Current staging of renal cell carcinoma. Urol Clin North Am 2003; 30:481-497.
2. Rini BI, Vogelzang NJ. Prognostic factors in renal carcinoma. Semin Oncol 2000; 27:213-220.
3. Gettman MT, Blute ML, Spotts B, et al. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001; 91:354-361.
4. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090-1095; quiz 1295.
5. Ficarra V, Righetti R, Pilloni S, et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 2002; 41:190-198.
6. Krejci KG, Blute ML, Cheville JC, et al. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome. Urology 2003; 62:641-646.
7. Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997; 157:2067-2070.
8. Levy DA, Slaton JW, Swanson DA, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159:1163-1167.
9. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999; 162:1930-1933.
10. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994; 12:206-212.
11. Aref I, Bociek RG, Salhani D. Is post-operative radiation for renal cell carcinoma justified? Radiother Oncol 1997; 43:155-157.
12. Stein M, Kuten A, Halpern J, et al. The value of postoperative irradiation in renal cell cancer. Radiother Oncol 1992; 24:41-44.
13. Migliari R, Muscas G, Solinas A, et al. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? J Chemother 1995; 7:240-245.
14. Basting R, Corvin S, Handel D, et al. Adjuvant immunotherapy in renal cell carcinoma - comparison of interferon alpha treatment with an untreated control. Anticancer Res 1999; 19:1545-1548.
15. Jeon SH, Chang SG, Kim JI. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. Anticancer Res 1999; 19:5593-5597.
16. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19:425-431.
17. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21:1214-1222.
18. Kirchner HH, Anton P, Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 1995; 13:171-173.
19. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: fiveyear results of a prospective randomized study. Cancer 1996; 77:2560-2566.
20. Doehn C, Richter A, Lehmacher W, et al. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Folia Biol (Praha) 2003; 49:69-73.
21. Repmann R, Goldschmidt AJ, Richter A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res 2003; 23:969-974.
22. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363:594-599.
23. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997; 80:1198-1220.
24. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001; 19:148-154.
25. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(suppl 1):S55-S57.
26. Negrier S, Maral J, Drevon M, et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 2000; 6(suppl 1):S93-S98.
27. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-3132.
28. Bordin V, Giani L, Meregalli S, et al. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol Int 2000; 64:3-8.
29. Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer 2004; 90:1156-1162.
30. Baaten G, Voogd AC, Wagstaff J. A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. Eur J Cancer 2004; 40:1127-1144.
31. Kirchner GI, Franzke A, Buer J, et al. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol 1998; 46:5-10.
32. Piga A, Giordani P, Quattrone A, et al. A phase II study of interferon alpha and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma. Cancer Immunol Immunother 1997; 44:348-351.
33. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Tumori 1993; 79:397-400.
34. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: workgroup no. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80:992-993.
35. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655-1659.
36. Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferonalfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: a randomised trial. Lancet 2001; 358:966-970.
37. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21:3133-3140.
38. Escudier B, Szczlyik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 2005; 23(16 suppl):380s.
39. Motzer RJ, Rini BI, Michaelson BG, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(16 suppl):380s.